Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 24OTHER 19OTHER_GOV 3NIH 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Neoplasm Metastasis 3Breast Neoplasms 3Prostatic Neoplasms 2Osteoporosis 2Neoplasms, Plasma Cell 1Multiple Myeloma 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 26Prednisone 16Magnetic Resonance Spectroscopy 16Specimen Handling 15PROSTVAC 14Biopsy 12Goserelin 11bicalutamide 10Leuprolide 9sargramostim 8Estramustine 8Radiotherapy 7Lycopene 7High-Intensity Focused Ultrasound Ablation 7Flutamide 7Bevacizumab 7enzalutamide 6Thalidomide 6Mitoxantrone 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6ixabepilone 5olaparib 4cediranib 4Tomography, X-Ray Computed 4Radiation 4Nivolumab 4Magnetic Resonance Imaging 4Androgen Antagonists 4Amplified Fragment Length Polymorphism Analysis 4temsirolimus 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Prostatic Neoplasms × Zoledronic Acid × Clear all
NCT00554918 2013-08-07

Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy

National Cancer Institute (NCI)

Phase 2 Completed
300 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00039104 2013-06-05

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
50 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡